Corvus Pharmaceuticals Inc (NASDAQ: CRVS) started the day on Wednesday, with a price increase of 3.11% at $3.98, before settling in for the price of $3.86 at the close. Taking a more long-term approach, CRVS posted a 52-week range of $1.75-$10.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 8.47% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 8.47%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 62.75%. This publicly-traded company’s shares outstanding now amounts to $68.17 million, simultaneously with a float of $53.32 million. The organization now has a market capitalization sitting at $306.91 million. At the time of writing, stock’s 50-day Moving Average stood at $3.81, while the 200-day Moving Average is $5.29.
Corvus Pharmaceuticals Inc (CRVS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Corvus Pharmaceuticals Inc’s current insider ownership accounts for 30.86%, in contrast to 28.91% institutional ownership. According to the most recent insider trade that took place on Jun 27 ’25, this organization’s Director sold 1,176,332 shares at the rate of 4.16, making the entire transaction reach 4,891,894 in total value, affecting insider ownership by 7,165,006. Preceding that transaction, on Jun 27 ’25, Company’s Director sold 1,176,332 for 4.16, making the whole transaction’s value amount to 4,891,894. This particular insider is now the holder of 7,165,006 in total.
Corvus Pharmaceuticals Inc (CRVS) Earnings and Revenue Records
Corvus Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 62.75% and is forecasted to reach -0.65 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 14.69% through the next 5 years, which can be compared against the 8.47% growth it accomplished over the previous five years trading on the market.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
Let’s observe the current performance indicators for Corvus Pharmaceuticals Inc (CRVS). It’s Quick Ratio in the last reported quarter now stands at 4.90.
In the same vein, CRVS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.98, a figure that is expected to reach -0.13 in the next quarter, and analysts are predicting that it will be -0.65 at the market close of one year from today.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
If we take a close look at the recent performances of Corvus Pharmaceuticals Inc (NASDAQ: CRVS), its last 5-days Average volume was 2.31 million that shows progress from its year to date volume of 0.9 million. During the previous 9 days, stock’s Stochastic %D was recorded 48.01% While, its Average True Range was 0.33.
Raw Stochastic average of Corvus Pharmaceuticals Inc (CRVS) in the period of the previous 100 days is set at 47.68%, which indicates a major rise in contrast to 40.19% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 92.76% that was higher than 84.97% volatility it exhibited in the past 100-days period.
